GR1008234B - Parenteral formulation of triazole antifungal agent and method for preparation thereof - Google Patents

Parenteral formulation of triazole antifungal agent and method for preparation thereof

Info

Publication number
GR1008234B
GR1008234B GR20130100315A GR20130100315A GR1008234B GR 1008234 B GR1008234 B GR 1008234B GR 20130100315 A GR20130100315 A GR 20130100315A GR 20130100315 A GR20130100315 A GR 20130100315A GR 1008234 B GR1008234 B GR 1008234B
Authority
GR
Greece
Prior art keywords
preparation
antifungal agent
parenteral formulation
triazole antifungal
active ingredient
Prior art date
Application number
GR20130100315A
Other languages
Greek (el)
Inventor
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Αναστασια Λεωνιδα Καλασκανη
Βασιλικη Χρηστου Σαμαρα
Ευσταθια Βαιλειου Μυλουλη
Μορφης Νικολαου Αμπατζης
Ευαγγελος Ανδρεα Καραβας
Χριστινα-Χρυση Ηλια Κιζιριδη
Original Assignee
"Φαρματεν Α.Β.Ε.Ε.",
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "Φαρματεν Α.Β.Ε.Ε.", filed Critical "Φαρματεν Α.Β.Ε.Ε.",
Priority to GR20130100315A priority Critical patent/GR1008234B/en
Priority to EP14726076.4A priority patent/EP3003265A1/en
Priority to PCT/EP2014/001285 priority patent/WO2014191080A1/en
Publication of GR1008234B publication Critical patent/GR1008234B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

The present invention relates to pharmaceutical compositions for parenteral administration comprising Voriconazole or pharmaceutical acceptable salt thereof as the active ingredient and a solubilizing agent such as hydroxypropyl beta cyclodextrin in order to achieve increased solubility of the active ingredient. The present invention also provides a method of preparation of such composition.
GR20130100315A 2013-05-27 2013-05-27 Parenteral formulation of triazole antifungal agent and method for preparation thereof GR1008234B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GR20130100315A GR1008234B (en) 2013-05-27 2013-05-27 Parenteral formulation of triazole antifungal agent and method for preparation thereof
EP14726076.4A EP3003265A1 (en) 2013-05-27 2014-05-13 Parenteral formulation of triazole antifungal agent and method for preparation thereof
PCT/EP2014/001285 WO2014191080A1 (en) 2013-05-27 2014-05-13 Parenteral formulation of triazole antifungal agent and method for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20130100315A GR1008234B (en) 2013-05-27 2013-05-27 Parenteral formulation of triazole antifungal agent and method for preparation thereof

Publications (1)

Publication Number Publication Date
GR1008234B true GR1008234B (en) 2014-06-24

Family

ID=50792404

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20130100315A GR1008234B (en) 2013-05-27 2013-05-27 Parenteral formulation of triazole antifungal agent and method for preparation thereof

Country Status (3)

Country Link
EP (1) EP3003265A1 (en)
GR (1) GR1008234B (en)
WO (1) WO2014191080A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232577B (en) 2014-04-25 2019-02-22 味之素株式会社 Immunostimulant
EP3511318A1 (en) 2015-10-28 2019-07-17 Ajinomoto Co., Inc. Immunostimulating agent
CN113975236B (en) * 2021-12-08 2023-03-31 海南鑫开源医药科技有限公司 Voriconazole dry suspension and preparation process thereof
CN116570558B (en) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 Voriconazole ophthalmic nanometer slow-release composition and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
EP2467379B1 (en) * 2009-08-19 2016-03-02 ratiopharm GmbH Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
EP2720723B1 (en) * 2011-06-15 2018-04-11 Synthon BV Stabilized voriconazole composition
EP2561863A1 (en) * 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole

Also Published As

Publication number Publication date
EP3003265A1 (en) 2016-04-13
WO2014191080A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
MX2019005379A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX361590B (en) Topical delivery of skin compositions having low ph.
MX2018015709A (en) Azabenzimidazole derivatives as pi3k beta inhibitors.
MY187047A (en) Selective pyy compounds and uses thereof
IL266964A (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
PH12015501096A1 (en) Composition for immediate and extended release
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
IN2013MU03583A (en)
MX2018004304A (en) Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors.
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
EP2987786A4 (en) Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component
GR1008234B (en) Parenteral formulation of triazole antifungal agent and method for preparation thereof
EA201590752A1 (en) PYRAMIDINDION DERIVATIVES PREPARATIONS
WO2014166836A8 (en) Growth hormone compound formulation
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
MX2017002544A (en) Isoquinolinone derivatives useful in the treatment of cancer.
BR112013025610A2 (en) use of a live avian metapneumovirus and pharmaceutical composition
MX2017002627A (en) Derivatives of macrocyclic n-aryl-2-amino-4-aryl-pyrimidine polyethers as inhibitors of ftl3 and jak.
PH12018501487A1 (en) Galenic formulation comprising a topical drug
MX2017002747A (en) Derivatives of macrocyclic n-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of ftl3 and jak.
GR1008818B (en) Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20140718